Literature DB >> 31822038

Clonal hierarchy of main molecular lesions in acute myeloid leukaemia.

Zdenka Herudkova1, Martin Culen1,2,3, Adam Folta2, Ivana Jeziskova2, Jana Cerna2, Tomas Loja3, Nikola Tom3, Jiri Smejkal2, Lukas Semerad2, Dana Dvorakova1,2, Jiri Mayer1,2,3, Zdenek Racil1,2,3.   

Abstract

Genetic mutations in acute myeloid leukaemia (AML) are assumed to occur in a sequential order; however, the predominant hierarchical roles of specific mutated genes have not been fully described. In this study, we aimed to determine the clonal involvement of the most frequent AML-associated mutations. Using a targeted sequencing panel for 18 genes, we traced changes and relative clonal contribution of mutations in 52 patients. We analysed 35 pairs of diagnosis and relapse samples, 27 pairs of primary samples and corresponding patient-derived xenografts, and 34 pairs of total leukocytes and corresponding isolated primitive cells or blast populations. In both relapse and xenografts, we observed conservation of main leukaemic clones and variability was limited to subclones with late-acquired mutations. AML evolution thus mainly involved modification of subclones while the clonal background remained unchanged. NPM1 mutations were identified as the most probable leukaemia-transformation lesion, remaining conserved in contrast to high variation of accompanying subclonal FLT3 and NRAS mutations. DNMT3A mutations represented the most stable mutations forming a preleukaemic background in most samples. Mutations in genes IDH1/2, TET2, RUNX1, ASXL1 and U2AF1 were detected both as preleukaemic and as subclonal lesions, suggesting a non-specific order of acquisition.
© 2019 British Society for Haematology and John Wiley & Sons Ltd.

Entities:  

Keywords:  acute myeloid leukaemia; clonality; mutations; patient-derived xenograft; relapse

Year:  2019        PMID: 31822038     DOI: 10.1111/bjh.16341

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  2 in total

Review 1.  NPM1-Mutated Myeloid Neoplasms with <20% Blasts: A Really Distinct Clinico-Pathologic Entity?

Authors:  Fabio Forghieri; Vincenzo Nasillo; Ambra Paolini; Francesca Bettelli; Valeria Pioli; Davide Giusti; Andrea Gilioli; Corrado Colasante; Gloria Acquaviva; Giovanni Riva; Patrizia Barozzi; Rossana Maffei; Leonardo Potenza; Roberto Marasca; Claudio Fozza; Enrico Tagliafico; Tommaso Trenti; Patrizia Comoli; Giuseppe Longo; Mario Luppi
Journal:  Int J Mol Sci       Date:  2020-11-26       Impact factor: 5.923

Review 2.  Human acute myeloid leukemia stem cells: evolution of concept.

Authors:  Dong-Yeop Shin
Journal:  Blood Res       Date:  2022-04-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.